AQUABAC® is produced from a strain of Bacillus thuringiensis subspecies israelensis (BTI), a naturally occurring bacterium that produces a crystalline protein toxic (crystal) and a spore. The larval activity of AQUABAC formulations and all other BTI formulations is due to the presence of the protein toxin. The spore has no larvicidal activity. AQUABAC formulations are unique and specifically manufactured to enhance the toxin’s larvicide effects and to ensure the toxin’s biological stability. AQUABAC formulations are produced in the United States to strict manufacturing specifications, ensuring that the products are of high quality and without any harmful contaminants. The potency of AQUABAC is controlled within specific limits using bioassay procedure based on toxicity to larvae of Aedes aegypti. Quality control bioassays are conducted prior to the release of each lot of product. Other analyses are conducted on each lot to ensure that there are no microbial contaminants present in the formulation.